- Home
- BDRX vs ZVSA Comparison
BDRX vs ZVSA Comparison
Compare BDRX & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- ZVSA
- Stock Information
- Founded
- BDRX 2000
- ZVSA 2014
- Country
- BDRX United Kingdom
- ZVSA United States
- Employees
- BDRX N/A
- ZVSA N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- ZVSA Health Care
- Exchange
- BDRX Nasdaq
- ZVSA Nasdaq
- Market Cap
- BDRX 2.4M
- ZVSA 2.5M
- IPO Year
- BDRX N/A
- ZVSA N/A
- Fundamental
- Price
- BDRX $3.93
- ZVSA $1.10
- Analyst Decision
- BDRX Strong Buy
- ZVSA Strong Buy
- Analyst Count
- BDRX 1
- ZVSA 1
- Target Price
- BDRX $200.00
- ZVSA $240.00
- AVG Volume (30 Days)
- BDRX 381.2K
- ZVSA 243.8K
- Earning Date
- BDRX 12-27-2024
- ZVSA 11-14-2024
- Dividend Yield
- BDRX N/A
- ZVSA N/A
- EPS Growth
- BDRX N/A
- ZVSA N/A
- EPS
- BDRX N/A
- ZVSA N/A
- Revenue
- BDRX $104,895.00
- ZVSA N/A
- Revenue This Year
- BDRX N/A
- ZVSA N/A
- Revenue Next Year
- BDRX N/A
- ZVSA N/A
- P/E Ratio
- BDRX N/A
- ZVSA N/A
- Revenue Growth
- BDRX N/A
- ZVSA N/A
- 52 Week Low
- BDRX $3.50
- ZVSA $0.98
- 52 Week High
- BDRX $74.00
- ZVSA $25.00
- Technical
- Relative Strength Index (RSI)
- BDRX 36.40
- ZVSA 41.83
- Support Level
- BDRX $4.14
- ZVSA $0.99
- Resistance Level
- BDRX $4.39
- ZVSA $1.20
- Average True Range (ATR)
- BDRX 0.57
- ZVSA 0.08
- MACD
- BDRX -0.06
- ZVSA 0.04
- Stochastic Oscillator
- BDRX 3.34
- ZVSA 54.55
About BDRX Biodexa Pharmaceuticals plc American Depositary Shs
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.